Minerva Neurosciences (NASDAQ:NERV) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Minerva Neurosciences (NASDAQ:NERV) from a sell rating to a hold rating in a research note released on Saturday.

A number of other equities analysts have also weighed in on the stock. Citizens Jmp began coverage on shares of Minerva Neurosciences in a report on Wednesday, April 15th. They issued a “market outperform” rating and a $14.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Minerva Neurosciences in a research note on Wednesday, June 24th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Minerva Neurosciences currently has a consensus rating of “Hold” and a consensus target price of $10.50.

Minerva Neurosciences Stock Performance

NASDAQ:NERV opened at $4.62 on Friday. The firm has a market cap of $215.25 million, a P/E ratio of -0.16 and a beta of -0.10. Minerva Neurosciences has a fifty-two week low of $1.76 and a fifty-two week high of $12.46. The firm has a 50-day simple moving average of $4.51 and a two-hundred day simple moving average of $5.43.

Minerva Neurosciences (NASDAQ:NERV) last issued its earnings results on Friday, August 7th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.19) by $0.05. On average, equities research analysts predict that Minerva Neurosciences will post -0.2 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of NERV. Janus Henderson Group PLC bought a new stake in shares of Minerva Neurosciences during the 4th quarter valued at about $36,000. OMERS ADMINISTRATION Corp bought a new position in shares of Minerva Neurosciences in the 1st quarter worth approximately $62,000. Cannon Global Investment Management LLC bought a new position in shares of Minerva Neurosciences in the 1st quarter worth approximately $107,000. State Street Corp boosted its holdings in shares of Minerva Neurosciences by 45.4% in the fourth quarter. State Street Corp now owns 24,019 shares of the biopharmaceutical company’s stock worth $97,000 after buying an additional 7,500 shares during the last quarter. Finally, Bank of America Corp DE boosted its holdings in shares of Minerva Neurosciences by 78,272.5% in the first quarter. Bank of America Corp DE now owns 39,970 shares of the biopharmaceutical company’s stock worth $241,000 after buying an additional 39,919 shares during the last quarter. 34.56% of the stock is owned by hedge funds and other institutional investors.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc is a clinical?stage biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company’s research and development efforts are directed toward addressing unmet needs in psychiatric and neurological conditions, leveraging its expertise in neuropharmacology and receptor modulation. Minerva’s goal is to bring forward differentiated molecules that can offer improved efficacy and safety profiles compared to existing treatments.

The company’s most advanced programs include roluperidone (formerly MIN-101), which has been investigated for the treatment of negative symptoms of schizophrenia, and MIN-117, a novel serotonergic agent being evaluated in major depressive disorder.